Guggenheim Capital LLC acquired a new position in shares of Guardant Health Inc (NASDAQ:GH) in the 4th quarter, Holdings Channel reports. The fund acquired 56,362 shares of the company’s stock, valued at approximately $4,404,000.
Other large investors also recently modified their holdings of the company. UBS Group AG raised its position in Guardant Health by 14.9% in the 4th quarter. UBS Group AG now owns 19,930 shares of the company’s stock valued at $1,557,000 after purchasing an additional 2,589 shares during the last quarter. Lord Abbett & CO. LLC raised its position in Guardant Health by 45.6% in the 4th quarter. Lord Abbett & CO. LLC now owns 349,940 shares of the company’s stock valued at $27,344,000 after purchasing an additional 109,651 shares during the last quarter. Handelsbanken Fonder AB raised its position in Guardant Health by 30.3% in the 4th quarter. Handelsbanken Fonder AB now owns 43,000 shares of the company’s stock valued at $3,360,000 after purchasing an additional 10,000 shares during the last quarter. Van ECK Associates Corp raised its position in Guardant Health by 12.8% in the 4th quarter. Van ECK Associates Corp now owns 98,627 shares of the company’s stock valued at $7,707,000 after purchasing an additional 11,156 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in Guardant Health in the 4th quarter valued at $2,364,000. Institutional investors and hedge funds own 81.56% of the company’s stock.
Several analysts recently commented on the stock. Citigroup assumed coverage on shares of Guardant Health in a research report on Monday, January 6th. They issued a “buy” rating and a $100.00 price target for the company. Guggenheim initiated coverage on shares of Guardant Health in a research note on Friday, February 21st. They issued a “buy” rating and a $103.00 price objective on the stock. Zacks Investment Research cut shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 27th. BidaskClub cut shares of Guardant Health from a “buy” rating to a “hold” rating in a research note on Wednesday, March 11th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $125.00 price objective on shares of Guardant Health in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $106.71.
In other news, CFO Derek A. Bertocci sold 19,100 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $60.65, for a total transaction of $1,158,415.00. Following the transaction, the chief financial officer now directly owns 100,333 shares of the company’s stock, valued at approximately $6,085,196.45. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Samir Kaul sold 25,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $82.38, for a total transaction of $2,059,500.00. Following the transaction, the director now directly owns 1,302 shares in the company, valued at $107,258.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,328 shares of company stock worth $4,030,768. Corporate insiders own 13.00% of the company’s stock.
Shares of GH opened at $65.84 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 8.00 and a current ratio of 8.21. The stock has a market capitalization of $6.17 billion and a P/E ratio of -78.38. The company’s fifty day moving average is $76.51 and its two-hundred day moving average is $74.98. Guardant Health Inc has a 1 year low of $55.90 and a 1 year high of $112.21.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.03. Guardant Health had a negative net margin of 33.84% and a negative return on equity of 10.02%. The business had revenue of $62.90 million for the quarter, compared to analysts’ expectations of $54.87 million. During the same period in the prior year, the company posted ($0.30) EPS. The business’s revenue for the quarter was up 91.2% on a year-over-year basis. Sell-side analysts predict that Guardant Health Inc will post -1.64 EPS for the current year.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
See Also: What is a trade deficit?
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health Inc (NASDAQ:GH).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.